9
Participants
Start Date
July 31, 2014
Primary Completion Date
July 31, 2017
Study Completion Date
December 31, 2017
Abraxane
125mg/m2, IV, on days 1,8 \& 15 of each 28 day cycle, up to 6 cycles.
Gemcitabine
1000mg/m2, IV, on days 1,8 \& 15 of a 28 day cycle, up to 6 cycles.
Addenbrookes Hospital, Cambridge
Collaborators (2)
Cambridge University Hospitals NHS Foundation Trust
OTHER
Cancer Research UK
OTHER
Celgene
INDUSTRY
CCTU- Cancer Theme
OTHER